SC
AEGR

Steven Cohen’s Aegerion Pharmaceuticals AEGR Stock Holding History

Steven Cohen’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-1,854,600
Closed -$38.8M – 880
2014
Q4 		$38.8M Buy
1,854,600
+1,097,100
+145% +$27.6M 0.27% 119
2014
Q3 		$25.3M Sell
757,500
-166,200
-18% -$5.16M 0.19% 149
2014
Q2 		$29.6M Buy
+923,700
New +$34.4M 0.19% 148

Other funds holding AEGR

SCM
Scopia Capital Management New York $112M AUM 48.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Steven Cohen's AEGR Position: Q1 2015 in Review

Steven Cohen sold out of Aegerion Pharmaceuticals (AEGR) in Q1 2015, closing a stake of 1,854,600 shares — an estimated $38.8M sold.

Steven Cohen first reported a position in AEGR in Q2 2014 and held it in 3 quarters. The position peaked at $38.8M in Q4 2014. 99 funds tracked by Wall St. Rank hold AEGR as of Q1 2015.

  • Steven Cohen reported no remaining Aegerion Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
  • Steven Cohen sold 1,854,600 Aegerion Pharmaceuticals shares in Q1 2015, an estimated $38.8M.
  • Steven Cohen first reported a position in Aegerion Pharmaceuticals in Q2 2014 and held it in 3 quarters.
  • Steven Cohen's Aegerion Pharmaceuticals position peaked at $38.8M in Q4 2014.
  • 99 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q1 2015.

Based on Point72 Asset Management's 13F filing for Q1 2015, filed 15 May 2015.